secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001628280-23-000666
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals enters $32.5M term loan facility with Hercules Capital
-------------------------------------------------------------------------

- Second Amended and Restated Loan with Hercules Capital provides $32.5M term loan; replaces prior facility.
- No amortization payments required before Oct 2024, extendable to Jan 2026 if conditions met.
- Interest rate of prime + 3.15%, floor 10.15%; prepayment premium up to 3%.
- Minimum liquidity covenant of $20M (or $10M after conditions); collateral excludes IP.
- Hercules gets participation right up to $1M in future equity offerings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023000666/0001628280-23-000666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023000666/xfor-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-000666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer